Michael L. Homiski
Pfizer (United States)(US)
Publications by Year
Research Areas
Carcinogens and Genotoxicity Assessment, DNA Repair Mechanisms, Chemical Synthesis and Analysis, Genetically Modified Organisms Research, Genomics and Chromatin Dynamics
Most-Cited Works
- → Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)(2011)107 cited
- → Yeast DEL assay detects clastogens(2005)43 cited
- → Development and validation of an in vitro micronucleus assay platform in TK6 cells(2012)39 cited
- → Assessing the genotoxicity of N‐nitrosodiethylamine with three in vivo endpoints in male Big Blue® transgenic and wild‐type C57BL/6N mice(2024)12 cited
- → Concordance analysis of an in vitro micronucleus screening assay and the regulatory chromosome aberration assay using pharmaceutical drug candidates(2009)11 cited
- → Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes(2009)8 cited
- → Experiments in the EpiDerm 3D Skin In Vitro Model and Minipigs In Vivo Indicate Comparatively Lower In Vivo Skin Sensitivity of Topically Applied Aneugenic Compounds(2021)5 cited
- → 2‐Hydroxypyridine N‐Oxide is not genotoxic in vivo(2019)4 cited